TOUCH Therapy

Touch Therapeutics is a preclinical-stage biotechnology company pioneering a novel class of targeted protein degraders designed to address "undruggable" targets located within cellular organelles or on the cell membrane. The company's proprietary TOUCH (Targeted Organelle Ubiquitin-mediated CHaperone) platform utilizes chimeric molecules to redirect the cell's internal degradation machinery to specific proteins in the mitochondria, endoplasmic reticulum, and other compartments. By expanding the scope of protein degradation beyond the cytosol, Touch Therapeutics aims to develop first-in-class therapies for hard-to-treat cancers and other diseases driven by organellar dysfunction. The company is currently focused on validating its platform across various high-value oncology targets that have remained elusive to traditional therapeutic approaches.